Mounjaro 7.5 mg

About this Medicine

Mounjaro 7.5 mg KwikPen offers a novel approach for adults managing type 2 diabetes and those eligible for weight loss support. As an innovative medication, Mounjaro (tirzepatide) works by activating two key receptors in the body: glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). This dual action helps to improve the body's natural ability to regulate blood sugar levels, especially after meals, by stimulating insulin release and reducing glucagon secretion when blood sugar is high. Simultaneously, it slows gastric emptying and influences appetite centers in the brain, contributing to a feeling of fullness and reduced food intake, which can lead to significant weight loss. Designed for convenient once-weekly administration, Mounjaro 7.5 mg is delivered via a pre-filled KwikPen, making self-injection straightforward for patients. It is an important part of a comprehensive treatment plan that must include a balanced diet and regular physical activity, as recommended by your healthcare provider. Understanding Mounjaro's mechanism of action is crucial for patients, as it underscores why lifestyle modifications are integral to achieving the best possible outcomes. This medication is not a substitute for insulin, nor is it intended for individuals with type 1 diabetes. Always consult with a healthcare professional to determine if Mounjaro 7.5 mg is an appropriate treatment option for your specific health needs and to discuss any potential side effects or interactions with other medications.